Citylabs lounge – Chiesi: Navigating the Future Regulatory Environment
Citylabs Lounge is a quarterly networking event for clinicians, academics and healthcare businesses located in the heart of Manchester’s Innovation District. These events are a valuable opportunity for people working in the healthcare and life science sector to engage with prospective clients and customers, as well as discuss some of the most topical issues of the day.
Navigating the Future
Life sciences and the healthcare sector play a vital role in the UK economy. Successfully navigating the vast regulations which impact this sector at international, national and local levels is not for the faint hearted.
Dr Diego Ardigo, Project Lead for the development and commercialization of biologics and Advanced Therapy Medicinal Products at global pharma company Chiesi, will be taking to the stage to discuss and explore the regulatory journey from the very earliest stages, including the essentials and pitfalls every company should know about. Sharing his unique insights into the challenges facing any organisation hoping to succeed in the life sciences and new technologies arena.
Dr Ardigo is a world-leading expert in this arena, having played a key role in the regulatory negotiations for both Europe’s first approved gene therapy and the first licensed stem cell therapy. He also has the distinction of playing a lead role in the team that won the prestigious UK Prix Galien orphan drug award in 2016.
8 - 8.30: Arrival & Breakfast
8.30 - 9.15 – Presentation and Q&A
A vision for the future of new technologies
Dr Diego Ardigo, Chiesi Farmaceutici
9.15 - 10 - Networking
This talk is proudly hosted by Chiesi Limited. – the UK affiliate of the international, privately-owned pharmaceutical company, based in Parma, Italy. In the UK, Chiesi employ over 300 dedicated employees, who are either based out of our new head office in Manchester, the Research and Development centre in Chippenham, or are part of our experienced field-based team. Established in 1935, Chiesi concentrates primarily on developing respiratory, cardiovascular and neonatological drugs, along with those for treating muscular and skeletal conditions